Abstract 581P
Background
Afatinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that is widely used to treatfor EGFR-mutated non-small cell lung cancer (NSCLC). The association between afatinib-related adverse events (AEs) and survival outcomes in patients with NSCLC has been rarely reported.
Methods
We retrospectively reviewed treatment-naȉive patients with NSCLC treated with afatinib for ≥1 month at Chang Gung Memorial Hospital. We analyzed the association between different types of AEs and clinical outcomes, including progression-free survival (PFS) and overall survival (OS).
Results
This study included 599 patients. The patients who experienced any grades of AEs had longer OS (median OS = 27.2 vs. 14.0 months, p = 0.019) than those who did not. As for PFS did not differ significantly between these two groups. Regarding the types of AE, the patients with either paronychia (median PFS =, 16.0 vs. 12.4 months, p = 0.011), skin lesions (median PFS =, 15.4 vs. 12.1 months, p = 0.042), or gastrointestinal (GI) symptoms, including nausea/vomiting (median PFS =, 18.8 vs. 14.3 months, p = 0.016), had experienced significantly better PFS than patients without these AEs. In addition, the patients with either paronychia (median OS =, 31.0 vs. 21.0 months, p < 0.001), skin lesions (median OS =, 29.3 vs. 20.9 months, p < 0.001), pruritus (median OS =, 31.6 vs. 24.7 months, p < 0.001), or mucositis/oral ulcers (median OS =, 30.2 vs. 25,5 months, p < 0.023) had showed better OS than patients without these AEs. After adjustment, the patients with experiencing paronychia and GI symptoms had favorable PFS, and those with paronychia, skin lesions, pruritus, or mucositis/oral ulcers had favorable OS.
Conclusions
Patients with NSCLC treated with patients undergoing afatinib and experiencing adverse events (AEs) had favorable survival PFS and OS. In addition, the associations between afatinib-related AEs and survival outcomes were type-dependent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract